GSK BHR Study (Sont)
Public ClinicalTrials.gov record NCT00920543. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind, Parallel Group, 40-week Comparison of Asthma Control Using Bronchial Hyperresponsiveness as an Additional Guide to Long-term Treatment in Adolescents and Adults Receiving Either Fluticasone Propionate/Salmeterol DISKUS Twice Daily or Fluticasone Propionate DISKUS Twice Daily (or Placebo BID if Asymptomatic)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to determine whether asthma control and reduced bronchial hyperresponsiveness could be achieved and maintained at a lower dose of inhaled corticosteroids with ADVAIR DISKUS twice-daily or FP twice-daily in adult and adolescent subjects with persistent asthma
Study identification
- NCT ID
- NCT00920543
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 464 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- FP 100mcg Drug
- FP 500mcg Drug
- FP 250mcg Drug
- FSC 100/50mcg Drug
- FSC 250/50mcg Drug
- FSC 500/50mcg Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2003 (Type not available)
- Primary completion
- Oct 2004 (Actual)
- Completion
- Oct 2004 (Actual)
- Last update posted
- Sep 1, 2016
2003 – 2004
United States locations
- U.S. sites
- 52
- U.S. states
- 30
- U.S. cities
- 48
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35209 | — |
| GSK Investigational Site | Phoenix | Arizona | 85006 | — |
| GSK Investigational Site | Tucson | Arizona | 85712 | — |
| GSK Investigational Site | Carmichael | California | 95608 | — |
| GSK Investigational Site | Palmdale | California | 93551 | — |
| GSK Investigational Site | San Diego | California | 92103 | — |
| GSK Investigational Site | San Diego | California | 92120 | — |
| GSK Investigational Site | San Diego | California | 92123 | — |
| GSK Investigational Site | San Jose | California | 95117 | — |
| GSK Investigational Site | San Jose | California | 95128 | — |
| GSK Investigational Site | Walnut Creek | California | 94598 | — |
| GSK Investigational Site | Colorado Springs | Colorado | 80907 | — |
| GSK Investigational Site | Denver | Colorado | 80206 | — |
| GSK Investigational Site | Wheat Ridge | Colorado | 80033 | — |
| GSK Investigational Site | Hartford | Connecticut | 06106 | — |
| GSK Investigational Site | Trumbull | Connecticut | 06611 | — |
| GSK Investigational Site | Bay Pines | Florida | 33744 | — |
| GSK Investigational Site | Gainesville | Florida | 32610 | — |
| GSK Investigational Site | Sarasota | Florida | 34233 | — |
| GSK Investigational Site | Chicago | Illinois | 60637 | — |
| GSK Investigational Site | Normal | Illinois | 61761 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46208 | — |
| GSK Investigational Site | Lafayette | Indiana | 47904 | — |
| GSK Investigational Site | Iowa City | Iowa | 52242 | — |
| GSK Investigational Site | Louisville | Kentucky | 40215 | — |
| GSK Investigational Site | New Orleans | Louisiana | 70119 | — |
| GSK Investigational Site | Baltimore | Maryland | 21224 | — |
| GSK Investigational Site | Petoskey | Michigan | 49770 | — |
| GSK Investigational Site | Minneapolis | Minnesota | 55407 | — |
| GSK Investigational Site | Butte | Montana | 59701 | — |
| GSK Investigational Site | Papillion | Nebraska | 68046 | — |
| GSK Investigational Site | Absecon | New Jersey | 8201 | — |
| GSK Investigational Site | Cherry Hill | New Jersey | 08003 | — |
| GSK Investigational Site | Rockville Centre | New York | 11570 | — |
| GSK Investigational Site | Asheville | North Carolina | 28801 | — |
| GSK Investigational Site | Statesville | North Carolina | 28625 | — |
| GSK Investigational Site | Canton | Ohio | 44718 | — |
| GSK Investigational Site | Sylvania | Ohio | 43560 | — |
| GSK Investigational Site | Toledo | Ohio | 43617 | — |
| GSK Investigational Site | Oklahoma City | Oklahoma | 73120 | — |
| GSK Investigational Site | Medford | Oregon | 97504 | — |
| GSK Investigational Site | Portland | Oregon | 97213 | — |
| GSK Investigational Site | Tigard | Oregon | 97223 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15213 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15241 | — |
| GSK Investigational Site | Lincoln | Rhode Island | 2865 | — |
| GSK Investigational Site | Charleston | South Carolina | 29407 | — |
| GSK Investigational Site | Nashville | Tennessee | 37203-1424 | — |
| GSK Investigational Site | Houston | Texas | 77090 | — |
| GSK Investigational Site | Charlottesville | Virginia | 22908 | — |
| GSK Investigational Site | Bellingham | Washington | 98226 | — |
| GSK Investigational Site | Morgantown | West Virginia | 26505 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00920543, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 1, 2016 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00920543 live on ClinicalTrials.gov.